关于研究药物的专家意见，第 31 卷，第 4 期，2022 年 4 月（

StephenW

关于研究药物的专家意见，第 31 卷，第 4 期，2022 年 4 月（特刊）现已在 Taylor & Francis Online 上在线提供。

肝细胞癌

这个新问题包含以下文章：

前言

前言：肝细胞癌：新兴疗法、药物靶点和基础知识空白
亚历山德罗·里佐 & Gennaro Palmiotti
页数：331-331 | DOI：10.1080/13543784.2022.2046732

社论

酪氨酸激酶抑制剂加免疫检查点抑制剂作为肝细胞癌的新辅助治疗：一种新兴选择？
亚历山德罗·里佐
页数：333-335 | DOI：10.1080/13543784.2021.1948533

药物评价

Camrelizumab：肝细胞癌的研究药物
徐斌 & 孙惠全
页数：337-346 | DOI：10.1080/13543784.2022.2022121

Durvalumab：不可切除肝细胞癌的研究药物
Marta Maestri、Maria Pallozzi、Francesco Santopaolo、Lucia Cerrito、Maurizio Pompili、Antonio Gasbarrini 和 Francesca Romana Ponziani
页数：347-360 | DOI：10.1080/13543784.2022.2033208

Atezolizumab-bevacizumab 加 Y-90 TARE 治疗肝细胞癌：临床前基本原理和正在进行的临床试验
亚历山德罗·迪·费德里科、亚历山德罗·里佐、里卡多·卡洛尼、安德里亚·德·吉里奥、里卡多·布鲁诺、达莉亚·里奇和乔瓦尼·布兰迪
页数：361-369 | DOI：10.1080/13543784.2022.2009455

看法

乐伐替尼加派姆单抗：治疗肝细胞癌的下一个前沿？
Alessandro Rizzo、Vincenzo Dadduzio、Angela Dalia Ricci、Francesco Massari、Alessandro Di Federico、Gennaro Gadaleta-Caldarola & Giovanni Brandi
页数：371-378 | DOI：10.1080/13543784.2021.1948532

审查

肝细胞癌的联合疗法加经动脉化疗栓塞：临床试验进展的快照
Zachary J. Brown、D Brock Hewitt 和 Timothy M Pawlik
页数：379-391 | DOI：10.1080/13543784.2022.2008355

用于治疗肝细胞癌的 FGFR4 抑制剂：治疗潜力概要
Hao Xie, Diego M Alem Glison & Richard D. Kim
页数：393-400 | DOI：10.1080/13543784.2022.2017879

卡博替尼加atezolizumab治疗晚期肝细胞癌：阐明临床前原理和临床试验
Antonella Cammarota、Valentina Zanuso、Antonio D'Alessio、Tiziana Pressiani、Nicola Personeni 和 Lorenza Rimassa
页数：401-413 | DOI：10.1080/13543784.2022.2032641

PD-L1、TMB 和其他肝细胞癌免疫治疗反应的潜在预测因子：它们如何协助药物临床试验？
亚历山德罗·里佐和安吉拉·达利亚·里奇
页数：415-423 | DOI：10.1080/13543784.2021.1972969

不可切除肝细胞癌的双重检查点封锁：临床试验中出现的机会
Antonella Cammarota、Valentina Zanuso、Antonio D'Alessio、Tiziana Pressiani、Silvia Bozzarelli、Nicola Personeni 和 Lorenza Rimassa
页数：425-435 | DOI：10.1080/13543784.2022.2042253

StephenW

Expert Opinion on Investigational Drugs, Volume 31, Issue 4, April 2022 (Special) is now available online on Taylor & Francis Online.

Hepatocellular carcinoma

This new issue contains the following articles:
       
Foreword

Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps
Alessandro Rizzo & Gennaro Palmiotti
Pages: 331-331 | DOI: 10.1080/13543784.2022.2046732

Editorial

Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?
Alessandro Rizzo
Pages: 333-335 | DOI: 10.1080/13543784.2021.1948533

Drug Evaluation

Camrelizumab: an investigational agent for hepatocellular carcinoma
Bin Xu & Hui-Chuan Sun
Pages: 337-346 | DOI: 10.1080/13543784.2022.2022121

Durvalumab: an investigational agent for unresectable hepatocellular carcinoma
Marta Maestri, Maria Pallozzi, Francesco Santopaolo, Lucia Cerrito, Maurizio Pompili, Antonio Gasbarrini & Francesca Romana Ponziani
Pages: 347-360 | DOI: 10.1080/13543784.2022.2033208

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
Alessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, Andrea De Giglio, Riccardo Bruno, Dalia Ricci & Giovanni Brandi
Pages: 361-369 | DOI: 10.1080/13543784.2022.2009455

Perspective

Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, Francesco Massari, Alessandro Di Federico, Gennaro Gadaleta-Caldarola & Giovanni Brandi
Pages: 371-378 | DOI: 10.1080/13543784.2021.1948532

Review

Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress
Zachary J. Brown, D Brock Hewitt & Timothy M Pawlik
Pages: 379-391 | DOI: 10.1080/13543784.2022.2008355

FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential
Hao Xie, Diego M Alem Glison & Richard D. Kim
Pages: 393-400 | DOI: 10.1080/13543784.2022.2017879

Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials
Antonella Cammarota, Valentina Zanuso, Antonio D’Alessio, Tiziana Pressiani, Nicola Personeni & Lorenza Rimassa
Pages: 401-413 | DOI: 10.1080/13543784.2022.2032641

PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo & Angela Dalia Ricci
Pages: 415-423 | DOI: 10.1080/13543784.2021.1972969

The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials
Antonella Cammarota, Valentina Zanuso, Antonio D’Alessio, Tiziana Pressiani, Silvia Bozzarelli, Nicola Personeni & Lorenza Rimassa
Pages: 425-435 | DOI: 10.1080/13543784.2022.2042253

StephenW

https://www.tandfonline.com/toc/ieid20/31/4?nav=tocList